Metastatic Pancreatic Cancer: ASCO Guideline Update
- Study type
- Clinical guideline
- Study name
- ASCO 2020
- Design
- American Society of Clinical Oncology (ASCO) guideline based on a systematic review; each recommendation with its type (evidence-based / informal consensus), quality of evidence and strength of recommendation
- Source
- J Clin Oncol · 2020
In plain words
This guideline from the American Society of Clinical Oncology (ASCO) helps doctors choose the best treatment for people with pancreatic cancer that has spread. Its main messages: the choice of first chemotherapy depends on the patient's general fitness; every patient should be tested for particular genetic changes (such as BRCA, MSI-H and NTRK fusion) because effective targeted treatments exist for them; and control of pain and symptoms, and palliative care, should be part of treatment from the start.
Key guideline recommendations
- Informal consensus; strength: strong
Early testing for actionable genomic alterations is recommended for patients who are likely candidates for subsequent treatment.
- Evidence quality: intermediate; strength: strong
Every patient with pancreatic cancer should be given information about clinical trials.
- Evidence quality: intermediate; strength: strong
FOLFIRINOX is recommended for patients who meet all of the following criteria: ECOG 0 to 1, a favourable comorbidity profile, and patient preference and a support system for aggressive medical therapy.
- Evidence quality: intermediate; strength: strong
Gemcitabine plus nab-paclitaxel is recommended for patients with ECOG 0 to 1 and a relatively favourable comorbidity profile.
- Evidence quality: intermediate; strength: moderate
Gemcitabine alone is recommended for patients with ECOG 2 or a comorbidity profile that precludes more aggressive regimens.
- Evidence quality: high; strength: strong
Pembrolizumab, a PD-1 checkpoint inhibitor, is recommended as second-line therapy for patients with mismatch repair deficiency or high microsatellite instability (dMMR/MSI-H).
- Evidence quality: low; strength: moderate
For patients with NTRK fusion-positive tumours, treatment with larotrectinib or entrectinib is recommended.
- Evidence quality: low; strength: moderate
For patients with a germline BRCA1 or BRCA2 mutation who have received first-line platinum-based chemotherapy for at least 16 weeks without disease progression, options for continued treatment include chemotherapy or the PARP inhibitor olaparib.
- Informal consensus; evidence quality: low; strength: moderate
Fluorouracil plus nanoliposomal irinotecan (or, if unavailable, fluorouracil plus irinotecan) is preferred as second-line therapy (after first-line gemcitabine-based therapy).
- Informal consensus; evidence quality: low; strength: moderate
Gemcitabine plus nab-paclitaxel may be offered as second-line therapy to patients who received first-line FOLFIRINOX and have ECOG 0 to 1.
- Informal consensus; evidence quality: low; strength: moderate
There are no data to recommend third-line or later therapy with a cytotoxic agent; participation in a clinical trial is encouraged.
- Informal consensus; evidence quality: low; strength: strong
For patients receiving active anticancer treatment outside a clinical trial, imaging to assess initial response should be performed 2 to 3 months after the start of treatment.
Study population
Patients with metastatic pancreatic cancer.
Clinical significance and place in guidelines
This is the latest published update of the ASCO guideline for metastatic pancreatic cancer in JCO that we found (2020). It was published before NAPOLI 3 (NALIRIFOX) and RASolute 302 (daraxonrasib) and does not cover these treatments; for newer recommendations see NCCN (version 4.2026) and the ESMO Express Update 2025.
Limitations
This update addressed only treatment after the first line and molecular testing, and endorsed the other recommendations from the 2018 version. The evidence for many second-line recommendations is "low" and based on informal consensus. Treatments approved after 2020 are not included.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.